Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.
IPO Year:
Exchange: NYSE
Website: https://ambrx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/25/2023 | $15.00 | Mkt Outperform | JMP Securities |
| 9/12/2023 | $26.00 | Buy | BTIG Research |
| 7/31/2023 | $29.00 | Outperform | RBC Capital Mkts |
| 6/14/2023 | $26.00 | Buy | B. Riley Securities |
| 6/2/2023 | $30.00 | Outperform | Oppenheimer |
| 5/19/2023 | $25.00 | Overweight | Cantor Fitzgerald |
| 4/7/2022 | $16.00 | Outperform | Robert W. Baird |
| 2/28/2022 | $6.00 | Neutral | Goldman Sachs |
4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)
4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)
4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)
4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)
4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)
4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)
4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)
4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)
4 - Ambrx Biopharma Inc. (0001836056) (Issuer)
4 - Ambrx Biopharma Inc. (0001836056) (Issuer)
JMP Securities initiated coverage of Ambrx Biopharma with a rating of Mkt Outperform and set a new price target of $15.00
BTIG Research initiated coverage of Ambrx Biopharma with a rating of Buy and set a new price target of $26.00
RBC Capital Mkts initiated coverage of Ambrx Biopharma with a rating of Outperform and set a new price target of $29.00
B. Riley Securities initiated coverage of Ambrx Biopharma with a rating of Buy and set a new price target of $26.00
Oppenheimer initiated coverage of Ambrx Biopharma with a rating of Outperform and set a new price target of $30.00
Cantor Fitzgerald initiated coverage of Ambrx Biopharma with a rating of Overweight and set a new price target of $25.00
Robert W. Baird initiated coverage of Ambrx Biopharma with a rating of Outperform and set a new price target of $16.00
Goldman Sachs initiated coverage of Ambrx Biopharma with a rating of Neutral and set a new price target of $6.00
4 - Ambrx Biopharma Inc. (0001836056) (Issuer)
15-12G - Ambrx Biopharma, Inc. (0001990550) (Filer)
8-K - Ambrx Biopharma, Inc. (0001990550) (Filer)
EFFECT - Ambrx Biopharma, Inc. (0001990550) (Filer)
S-8 POS - Ambrx Biopharma, Inc. (0001990550) (Filer)
S-8 POS - Ambrx Biopharma, Inc. (0001990550) (Filer)
S-8 POS - Ambrx Biopharma, Inc. (0001990550) (Filer)
S-8 POS - Ambrx Biopharma, Inc. (0001990550) (Filer)
S-8 POS - Ambrx Biopharma, Inc. (0001990550) (Filer)
POS AM - Ambrx Biopharma, Inc. (0001990550) (Filer)
25-NSE/A - Ambrx Biopharma, Inc. (0001990550) (Subject)
– Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., ("Ambrx" or the "Company") (NASDAQ:AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders. As previously announced, under the terms of the transaction, Ambrx shareholders will receive $28.00 per share in cash in connection with the closing of the transaction. Daniel J. O'Connor, Chief Executive Officer of Ambrx, said, "We want to thank our shareholders for their strong support of this transaction. With a steadfast focus on protein engineering innovation and some of the best ADC talent in t
SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ:AMAM), today announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for $28.00 per share in cash, representing an approximately 105% premium to Ambrx's closing stock price on January 5, 2024, for a total equity value of approximately $2.0 billion. "We are excited to reach this agreement with Johnson & Johnson for advancing scientific research to treat cancers with high unmet needs," said Daniel J. O'Connor, Chief Executive Officer of Ambrx. "With our deep and unique knowledge of precision engineering of protein ther
Portfolio of Clinical and Preclinical Programs, Including Lead Product Candidate ARX517, a Prostate-Specific Membrane Antigen (PSMA)-Targeting Antibody Drug Conjugate (ADC), Strengthens Johnson & Johnson's Commitment to Oncology Innovation Novel Technology Platform Sets Stage for the Development of Next Generation ADCs and Targeted Oncologic Therapeutics Johnson & Johnson (NYSE:JNJ) announced today it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx (NASDAQ:AMAM), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger
SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx, (NASDAQ:AMAM), today announced that the Company will be added to the NASDAQ Biotechnology Index (NASDAQ:NBI), effective prior to the market open on Monday, December 18, 2023. "2023 has been a transformational year for Ambrx, especially for our publicly held securities. We voluntarily transferred to Nasdaq from the New York Stock Exchange, we changed our parent company domicile to Delaware from the Cayman Islands and we terminated our ADS program, resulting in our common stock being listed on Nasdaq," said Daniel J. O'Connor, Chief Executive Officer of Ambrx. "Now, at the end of the year and due to these actions
Cohort 9 Following completion of the 21-day observation period at 3.4 mg/kg (Cohort 9), no dose limiting toxicities (DLTs) or serious adverse events (SAEs) were observed Two patients in Cohort 9 experienced rapid PSA reduction at three weeks post-treatment following the first ARX517 dose Cohort 8 The cohort (2.88 mg/kg) is now fully enrolled with 20 patients Recommended phase 2 dose expected by early next year SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ:AMAM), today announced a clinical update regarding its proprietary anti-PSMA antibody drug conjugate (ADC) ARX517 in the ongoing APEX-01 Phase 1 / 2 dose escalation and dose expansion clinical
Newly published data from the Phase 1 portion of the on-goingPhase 1 / 2 APEX-01 trial provide the following key points: Multiple efficacy endpoints demonstrate consistent and promising anti-cancer activity at therapeutic doses of 2.0 – 2.88 mg/kg (Cohorts 6-8) in heavily pretreated patients (median of 4 and maximum of 13 prior lines of therapy): 52% (12/23) of patients experienced a ≥50% PSA reduction81% (17/21) of patients experienced ≥50% circulating tumor DNA reduction50% (3/6) of patients with prior PSMA-targeted radionuclide therapy (TRT) experienced a ≥50% PSA reduction50% (2/4) experienced a >30% reduction in target lesion(s) A strong and highly differentiated safety profile obs
Newly published abstract regarding dose escalation patients provides key updates including: ≥50% PSA reduction observed across putative therapeutic dose levels ≥2.0 mg/kg – 3 of 3 in Cohort 6 (2.0 mg/kg), 2 of 3 in Cohort 7 (2.4 mg/kg) and 2 of 3 in Cohort 8 (2.88 mg/kg)No drug-related severe adverse events (SAEs) and no dose limiting toxicities (DLTs) observed in any cohortPharmacokinetic (PK) data indicated strong ADC stability preventing premature release of anticancer payload Ambrx to host a live event / webcast to discuss additional data presented at ESMO on Sunday, October 22, 2023, at 8 p.m. CEST / 2 p.m. ET SAN DIEGO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., o
SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the "Company") (NASDAQ:AMAM), today announced that it will host an in-person key opinion leader (KOL) event during the European Society for Medical Oncology (ESMO) Congress 2023. The event will take place on Sunday, October 22, 2023 from 8:00pm – 10:00pm CEST (2:00pm – 4:00pm ET) at the Santo Mauro Hotel in Madrid, Spain. Discussions will feature preliminary safety, efficacy, and pharmacokinetic (PK) data from APEX-01 (NCT04662580), a first-in-human study evaluating ARX517 in prostate cancer patients, which will be presented for the first time at ESMO 2023. The event will showcase presentations from prostate can
Morgan Stanley Fireside Chat Replay Now Available SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the "Company") (NASDAQ:AMAM), today announced that Daniel J. O'Connor, Chief Executive Officer and President of Ambrx, will participate in a fireside chat and one-on-one meetings at the Cantor Fitzgerald Global Healthcare conference, being held in New York, NY. Presentation details are below: Cantor Fitzgerald Global Healthcare Conference: Date: Wednesday, September 27, 2023Time: 10:20 AM ET A replay of Daniel J. O'Connor's Fireside Chat at the Morgan Stanley Annual Global Healthcare Conference is now available on the Events and Presentations section of the Am